Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to once-weekly islatravir + ulonivirine in virologically suppressed adults with HIV-1
2024-511041-19-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of islatravir and ulonivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Started Apr 2024; status: completed.
02
Drugs
islatravirulonivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-511041-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511041-19-00.